Literature DB >> 9092920

The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles.

S Biade1, C C Stobbe, J D Chapman.   

Abstract

The intrinsic radiosensitivity of tumor cells is most frequently reported for asynchronous populations, although cell cycle variation in radiosensitivity is known to be significant. Linear-quadratic analyses of survival data for asynchronous human tumor cells show wide variations in the alpha coefficient with smaller variations in the beta coefficient. HT-29 (colon), OVCAR10 (ovary) and A2780 (ovary) tumor cells with alpha coefficients of 0.03, 0.16 and 0.47 Gy(-1), respectively, and square-root of beta coefficients of 0.23-0.27 Gy(-1) for asynchronous populations were amenable to synchronization by mitotic selection. Selection procedures were optimized for each cell line and produced mitotic populations of >90%, approximately 80% and approximately 65% purity for HT-29, OVCAR10 and A2780 cells, respectively. Mitotic cells from each line exhibited similar and maximum radiosensitivities with alpha coefficients of approximately 1.3 Gy(-1) after irradiation with 137Cs gamma rays and after correction for genome multiplicity. Their relative radiosensitivities observed with asynchronous cells were maintained as they progressed through interphase of the cell cycle. All cells in early G1 phase exhibited a marked radioresistance relative to their sensitivity in mitosis, and maximum interphase radiosensitivity was observed near the G1/S-phase boundary. All cells became increasingly radioresistant as they moved through S phase, the effect being most pronounced for OVCAR10 cells and least pronounced for A2780 cells. HT-29 cells remained relatively radioresistant in G2 phase. The different interphase radiosensitivities observed for these cell lines were determined mainly by the single-hit inactivation mechanism. These studies clearly demonstrate the dominant role of single-hit inactivation in determining the intrinsic radiosensitivity of human tumor cells to 137Cs gamma rays, especially at doses of 2 Gy and less.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9092920

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  20 in total

1.  Differential proliferation dependence of alpha and beta damage in X-irradiated Chinese hamster cells.

Authors:  D Bartkowiak; W Nothdurft; E M Röttinger
Journal:  Strahlenther Onkol       Date:  1999-05       Impact factor: 3.621

2.  Conversations between chromatin modifications and DNA double strand break repair: a commentary.

Authors:  Michael J Hendzel; Roger A Greenberg
Journal:  Mutat Res       Date:  2013-08-27       Impact factor: 2.433

3.  Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.

Authors:  Jeho Jeong; Jung Hun Oh; Jan-Jakob Sonke; Jose Belderbos; Jeffrey D Bradley; Andrew N Fontanella; Shyam S Rao; Joseph O Deasy
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

4.  Silencing platelet-derived growth factor receptor-β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo.

Authors:  Ji-Dong Hong; Xia Wang; Yu-Ping Peng; Jiang-Hua Peng; Jun Wang; Ye-Ping Dong; Dan He; Zhen-Zi Peng; Qing-Song Tu; Liang-Fang Sheng; Mei-Zuo Zhong; Chao-Jun Duan
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

5.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Authors:  Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

6.  A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

Authors:  Ya-Ting Yang; Curt Balch; Samuel K Kulp; Michael R Mand; Kenneth P Nephew; Ching-Shih Chen
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

7.  Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells.

Authors:  Seiichiro Ishihara; Motoaki Yasuda; Akihiro Ishizu; Masayori Ishikawa; Hiroki Shirato; Hisashi Haga
Journal:  Oncotarget       Date:  2015-03-10

8.  A Mechanistic DNA Repair and Survival Model (Medras): Applications to Intrinsic Radiosensitivity, Relative Biological Effectiveness and Dose-Rate.

Authors:  Stephen Joseph McMahon; Kevin M Prise
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

Review 9.  Radiosensitization in prostate cancer: mechanisms and targets.

Authors:  Diego A Palacios; Makito Miyake; Charles J Rosser
Journal:  BMC Urol       Date:  2013-01-26       Impact factor: 2.264

10.  Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.

Authors:  Aaron T Wild; Nishant Gandhi; Sivarajan T Chettiar; Khaled Aziz; Rajendra P Gajula; Russell D Williams; Rachit Kumar; Kekoa Taparra; Jing Zeng; Jessica A Cades; Esteban Velarde; Siddharth Menon; Jean F Geschwind; David Cosgrove; Timothy M Pawlik; Anirban Maitra; John Wong; Russell K Hales; Michael S Torbenson; Joseph M Herman; Phuoc T Tran
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.